SAN FRANCISCO — Neoadjuvant chemo-immunotherapy led to significant downstaging prior to definitive surgery for patients with muscle-invasive urothelial cancer, according to data presented at ASCO Genitourinary Cancers Symposium.
Researchers observed this outcome among both cisplatin-eligible and cisplatin-ineligible patients.
“It’s exciting that we were able to not just meet but quite exceed … the null hypothesis,” researcher Jason Brown, MD, PhD, genitourinary medical oncologist with University Hospitals, told Healio.
Immune checkpoint inhibition is standard therapy